ReviewNanoscale advances2026
Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer's disease.
Review in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), as a common neurodegenerative disorder, seriously affects human health. However, the treatment of AD has always faced significant challenges and has attracted extensive attention in medical research. In recent years, nanoparticle-based therapeutic strategies have been identified as a promising direction in AD research due to their unique advantages and potential. These strategies leverage the distinctive physical and chemical properties of nanomaterials, enabling them to effectively traverse the blood-brain barrier and directly target pathological sites, thereby minimizing damage to normal tissues and enhancing therapeutic efficacy. This approach holds considerable promise for AD treatment. Current literature indicates that nanomedicines can deliver therapeutic agents, such as approved pharmaceuticals, natural compounds, antibodies, and metal nanoparticles, directly to lesion sites, thereby reducing collateral damage to healthy tissues and improving treatment outcomes. With continuous advancements in nanotechnology and ongoing scientific investigations, there is potential for developing safer and more effective treatment options for AD patients in the future. This review aims to summarize recent developments in nanoparticle-based strategies for AD therapy and elucidate their mechanisms of action, providing new insights for the future development and advancement of nanomedicines in this domain.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.